Anti-PSCA-A11-antibody-I-124 - ImaginAb

Drug Profile

Anti-PSCA-A11-antibody-I-124 - ImaginAb

Alternative Names: 124-I-anti-PSCA-A11-minibody - ImaginAb; 124I-A11-PSCA-minibody - ImaginAb; Anti-prostate-stem-cell-antigen-A11-antibody-I-124 - ImaginAb; Anti-PSCA-A11-minibody-I-124 - ImaginAb

Latest Information Update: 19 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of California at Los Angeles
  • Developer ImaginAb Inc; University of California at Los Angeles
  • Class Antibody diagnostics; Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bladder cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 26 May 2016 ImaginAb suspends a phase I trial in Bladder cancer (Diagnosis), Pancreatic cancer (Diagnosis) and Prostate cancer (Diagnosis) in USA due to temporary unavailability of anti-PSCA-A11-antibody-I-124(NCT02092948)
  • 14 Jan 2016 Anti-PSCA-A11-antibody-I-124 is still in phase I trials for Prostate cancer, Pancreatic cancer and Bladder cancer (Diagnosis) in USA
  • 01 Aug 2013 Phase-I clinical trials in Prostate cancer, Pancreatic cancer and Bladder cancer (diagnosis) in USA (IV) (NCT02092948)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top